Sanofi has added another string to its Pompe disease therapy bow, after getting FDA approval for Nexviazyme, its latest therapy for the rare, inherited disorder. The US regulator has approved ...
LuckyCase case formats are supported as default filters by node js dependency, in browser optionally if LuckyCase is loaded as well (bundled version).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results